Is a Six-Month Wet AMD Shot Finally Here?
Almost. Zenkuda, a new anti-VEGF drug from Kodiak Sciences, matched Eylea for vision gains in a Phase 3 trial with more than half of patients dosed only every six months. The data are a company press release, not a peer-reviewed paper, and the drug isn't FDA-approved yet. But for anyone worn out by the four-to-eight-week injection burden of wet AMD care, this is the first Phase 3 result showing most patients can hold their vision on just two shots a year.
Wet AMD is a disease where the drugs work and the schedule fails. Anti-VEGF injections cut two-year blindness by about 72% versus no treatment. But every four to eight weeks, forever, is a lot to sustain. In routine care, visits drift, shots stretch, and the early gains reverse. DAYBREAK asked whether twice a year could hold up. The answer, from a company press release: yes, for most patients.
The drugs already work. What breaks is the schedule.
Left alone, wet AMD is one of the fastest ways to go legally blind. In a meta-analysis of untreated eyes from pre-anti-VEGF trials, the share with vision worse than 20/200 rose from about 20% at baseline to roughly 76% by three years. Anti-VEGF injections cut the two-year rate of legal blindness by roughly 72%. That benefit depends entirely on the injections actually happening.
They often don't. In a real-world registry of 49,485 eyes, patients getting 4 or fewer injections in the first year lost vision on net; only those getting 5 to 10 gained. A European registry found about 25% of patients need shots every six weeks, and roughly 40% discontinue by year two. In one 98,821-eye US cohort, the initial letter gain reversed into a 5-letter net loss by year four as annual injection counts drifted from 7.5 down to 6.4. The schedule is the weak link.
What DAYBREAK actually showed
On September 28, 2026, Kodiak Sciences reported that DAYBREAK, its Phase 3 trial in treatment-naive wet AMD, hit its primary endpoint: Zenkuda produced non-inferior vision gains at one year against aflibercept 2 mg dosed every eight weeks. The dosing is the news. Under strict treat-to-dryness retreatment rules, 54% of Zenkuda patients were on a 24-week interval by the end of year one. Reported intraocular inflammation was 0%, and the cataract rate was lower than with aflibercept.
Two caveats live inside that result. This is a company press release, not a peer-reviewed paper. The exact letter-gain point estimates, the pre-specified non-inferiority margin, and per-arm sample sizes weren't disclosed. And Zenkuda has a mixed Phase 3 history: an earlier trial, DAZZLE, missed its primary vision endpoint against aflibercept in wet AMD, and a separate Phase 3, DAYLIGHT, hit its endpoint but reported intraocular inflammation in 3.3% of patients on monthly tarcocimab, versus 0.4% on aflibercept. DAYBREAK is the trial that clears the bar, on a six-month schedule the others couldn't touch. Kodiak plans to file for FDA approval in the fourth quarter of 2026.
Where Zenkuda would fit if it's approved
The gap between an eight-week schedule and a longer one has already been closing. Faricimab and aflibercept 8 mg both stretch intervals without giving up vision. What DAYBREAK adds is a six-month interval for most treatment-naive patients, which no Phase 3 has reached before.
| Drug | Vision vs Eylea 2 mg | Longest interval reached in pivotal trial | US approval status |
|---|---|---|---|
| Aflibercept 2 mg (Eylea) | Reference | 8 weeks (label) | Approved |
| Faricimab (Vabysmo) | Matched | 16 weeks (TENAYA and LUCERNE) | Approved |
| Aflibercept 8 mg (Eylea HD) | Matched | 24 weeks in a subset (PULSAR, year 2) | Approved |
| Tarcocimab tedromer (Zenkuda) | Matched (press release) | 24 weeks in a majority (DAYBREAK, year 1) | Not approved; filing planned Q4 2026 |
If wet AMD is already part of your life
If you're currently getting anti-VEGF injections, DAYBREAK doesn't change what to do today. Zenkuda isn't approved, the data are a press release, and switching drugs mid-treatment turns on how your eye is actually doing, which is your retina specialist's call.
The part worth acting on now isn't the new drug. It's the injection burden itself. If you're stretching, skipping, or dreading appointments, that pattern is exactly what's behind the four-to-six-year vision loss the registries keep finding. Two approved options were designed to lengthen intervals: faricimab (Vabysmo) and aflibercept 8 mg (Eylea HD). Both are worth raising with your retina specialist if the schedule is what stands between you and your vision. Zenkuda is worth revisiting once the FDA acts; the filing is expected in late 2026.
For wet AMD, the drugs already work. The next era will be measured in months between shots, not letters gained, and DAYBREAK is the first credible signal that six-month intervals are within reach. What could still send it back: the peer-reviewed data reading softer than the press release, longer-term safety signals from the earlier Zenkuda trials resurfacing, or the FDA disagreeing with Kodiak's read of the numbers.